After Hours
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility.
Stocks Info
Verona Pharma Plc ADR is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. The current market capitalization of Verona Pharma Plc ADR is $8.91B. A total of 15.62 million shares were traded on the day, compared to an average of 2.75M shares.
In the most recent transaction, Fisher Andrew sold 80,000 shares of VRNA for 11.53 per share on Jun 16 ’25. After the transaction, the General Counsel now owns 359,999 company shares. In a previous transaction on Jun 11 ’25, Hahn Mark W sold 400,000 shares at 11.40 per share. VRNA shares that Chief Financial Officer owns now total 12,278,992.
Among the insiders who sold shares, ZACCARDELLI DAVID disposed of 400,000 shares on Jun 11 ’25 at a per-share price of $11.40. This resulted in the President and CEO holding 13,190,168 shares of VRNA after the transaction. In another insider transaction, DAVID ZACCARDELLI bought 50,000 shares at $86.78 per share on Jun 11 ’25.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. In terms of 52-week highs and lows, VRNA has a high of $104.99 and a low of $18.51.
As of this writing, VRNA has an earnings estimate of $0.39 per share for the current quarter. EPS was calculated based on a consensus of 1.0 estimates, with a high estimate of $0.39 per share and a lower estimate of $0.39.
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. VRNA’s latest balance sheet shows that the firm has $148.38M in Cash & Short Term Investments as of fiscal 2021. There were $5.81M in debt and $33.42M in liabilities at the time. Its Book Value Per Share was $2.66, while its Total Shareholder’s Equity was $148.00M.
Analysts Opinion
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for VRNA is Buy with a score of 3.36.
